CareDx, Inc. has completed its acquisition of Naveris, extending its leadership into high-growth specialty oncology. The transaction, which was initially announced in April 2026, adds Naveris’s lead product, NavDx, to CareDx’s portfolio of precision diagnostic testing services. This strategic move expands CareDx’s estimated addressable market to more than $12 billion across transplant, specialty oncology, and cell therapy.

NavDx is a blood-based test designed to detect and monitor viral-mediated cancers, including human papillomavirus (HPV)-associated head and neck and anal cancers. It covers the entire patient journey from diagnosis through post-treatment molecular residual disease (MRD) surveillance. Notably, NavDx is the first and only Medicare-covered assay for HPV-driven head and neck and anal cancer MRD.

The commercial performance of NavDx has been strong, with over 130,000 tests reported to date. The test secured Medicare coverage in 2023 and carries an ADLT Medicare reimbursement rate of $1,800. In 2025, Naveris generated approximately $35 million in revenue, representing a year-over-year increase of more than 100%.

Financial Integration and Market Impact

Beginning in the third quarter of 2026, Naveris will be included in CareDx’s consolidated financial results. The integration aligns with CareDx’s growth model of commercializing category-leading, repeat molecular biomarker testing for patients with a high burden of disease.

John Hanna, President and Chief Executive Officer of CareDx, emphasized the strategic fit of the acquisition. He stated that NavDx fits CareDx’s growth model precisely and expressed confidence that the company has the platform and focus to scale the test. Hanna expects NavDx to be a meaningful contributor to CareDx’s growth from day one.

CareDx is a precision medicine diagnostics company focused on transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, the company aims to improve patient outcomes.

CareDx, Inc. has completed the sale of its Lab Products business to Eurobio Scientific for $171.2 million in cash, sharpening its focus on U.S. precision medicine Testing Services and Patient & Digital Solutions. The transaction, which closed on June 30, 2026, followed the receipt of required Swedish regulatory clearance. This strategic move allows CareDx to streamline its operating model and concentrate on high-value healthcare solutions for transplant patients and caregivers.

Transaction Details

Under the terms of the agreement, CareDx received $171.2 million in cash consideration at closing, subject to customary post-closing adjustments. The divestiture includes the company's In Vitro Diagnostic (IVD) PCR kits for rapid deceased donor HLA typing, IVD NGS-based kits for transplant recipient HLA typing globally, and IVD NGS-based monitoring assays for solid organ and stem cell transplant recipients outside of North America.

Strategic Impact

John Hanna, President and Chief Executive Officer of CareDx, stated that the transaction sharpens the company's focus on its core U.S. Precision Medicine Testing Services and Patient and Digital Solutions. He noted that the integrated model continues to deliver strong growth and that the sale simplifies the operating model while supporting disciplined capital allocation, including investments in high-growth areas such as specialty oncology.

Key Information

CareDx anticipates providing additional details regarding the financial impact of the transaction, including pro forma results, during its second quarter 2026 earnings call. Rothschild & Co. and Fenwick & West LLP represented CareDx, while TD Cowen and Kahn Partners represented Eurobio Scientific.